Amaç: Prostat kanseri olan hastaların lenf nodu metastazını öngörmek için etkili olacak faktörler araştırıldı. Materyal ve Metotlar: Ocak 2005 ile Şubat 2011 tarihleri arasında, kliniğimizde prostat kanseri tanısı ile radikal prostatektomi (RP) ve pelvik lenf nodu diseksiyonu (PLND) ya da sadece PLND yapılan toplam 218 hasta değerlendirildi. Preoperatif PSA, hasta yaşı, preoperatif prostat biyopsisi, klinik evre, nihai patoloji, radyolojik incelemeler değerlendirilerek lenf nodu invazyonunu etkileyen faktörler araştırıldı. Bulgular: Çalışmaya dahil edilen hastaların yaş ortalaması 63,26±6,87 (45-76) , ortalama PSA değeri 13,11 ng/dl ve TRUSG ile ortalama prostat boyutu 50,2 gr olarak bulundu. Operasyon esnasında frozen pozitifliği nedeniyle sadece PLND yapılan 18 hastanın hepsinde ve PLND-RP yapılan 210 hastanın 10’unda (toplam 28 hasta) lenf nodunda tümör metastazı saptandı. Biyopsideki tümörün yerleşimi açısından gruplar karşılaştırıldığında, bazal yerleşimli tümörlerde LNİ oranı daha yüksek saptandı. (p=0,047) Yapılan univariate analizde en yüksek prediktif doğruluğu %88,1 ile pozitif kor yüzdesi ve biyopside tümörün tek veya çift taraflı olması göstermekte iken bunu %87,6 ile total-PSA ve %87,1 ile biyopsi Gleason skoru izledi. Multivariate analizde ise total-PSA biyopside pozitif kor yüzdesi ve biyopsi gleason skoru anlamlı olarak bulundu (p
Objectives: To analyze the factors that will be effective in predicting lymph node metastasis in patients with prostate cancer Materials and Methods: Between January 2005 and February 2011, a total of 218 patients with prostate cancer had undergone radical prostatectomy (RP) and pelvic lymph node dissection (PLND), or just pelvic lymph node dissection in our clinic were evaluated. Preoperative PSA, patient age, preoperative prostate biopsy, clinical stage, final pathology, radiological examinations were evaluated to analyze the factors affecting lymph node invasion. Results: The average age of the patients were 63.26 ± 6.87 (45- 76). The mean PSA value was 13.11 ng/dl and the mean prostate size defined by TRUSG was 50.2 gr. Lymph node tumor metastasis was detected in postoperative pathological examination of 28 patients including all of the 18 patients who underwent only PLND due to positive frozen section and 10 of 210 patients who underwent PLND and RP. A higher rate of LNI was detected in tumors located in the basement when the biopsies of the tumor groups were compared in terms of location (p=0.047). The highest positive predictive accuracy was obtained as 88.1% with the percentage of positive core biopsy and whether the tumor was single-or double-sided, and followed by 87.60 with the total-PSA and 87.1 with biopsy Gleason score. In multivariate analyses, total-PSA, the percentage of the positive cores and the biopsy Gleason scores were found to be significant (p <0.02). Conclusion: We think our study will be helpful in selecting patients who will undergo pelvic lymph node dissection.
1. Walsh PC: Anatomic Radical Retropubic Prostatectomy; in Walsh PC, Retik AB, Vaughan ED, Wein AJ(Eds.): Campbell’s Urology 7. baskı, 1998: 2565-2588.
2. John N. Eble, G.S.e.a., ed. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs., World Health Organization Classification of Tumours International Agency for Research on Cancer (IARC): Lyon2004
3. Rosai J. Prostate and Seminal Vesicles. In: Rosai J, ed. Rosai and Ackerman’s Surgical Pathology. Vol 1. 9th ed. China: Mosby; 2004. p. 1361-1412
4. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemprorary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001; 58: 843- 48
5. Schröder FH, van der Cruijsen _ Koeter I, de Koning HJ, et al:Prostate cancer detection at low prostate spesific antigen. J Urol 2000; 163:806
6. James A. Easton, Peter T. Scardino. Radical prostatectomy; in Walsh PC, Retik AB, Stamey TA, Vaughen ED Jr, eds: Campbell’s Urology 8th ed. Philedelphia: WD Saunders Co; 2002 p.3080 – 106
7. Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol 2008;53:68–80
8. Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003;348:2491–9.
9. Thoeny HC, Triantafyllou A, Birkhaeuser FD, et al. Combined ultrasmall superparamagnetic particles of iron oxide–enhanced and diffusion-weighted magnetic resonance imaging reliably detect pelvic lymph node metastases in normalsized nodes of bladder and prostatecancer patients. Eur Urol 2009;55:761–9.
10. Wolf Jr JS, Cher M, Dall’era M, Presti Jr JC, Hricak H, Carroll PR. The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy.J Urol 1995;153:993–9.
11. Katz S, Rosen M. MR imaging and MR spectroscopy in prostate cancer management. Radiol Clin North Am 2006;44:723–34.
12. Tempany CM, McNeil BJ. Advances in biomedical imaging. JAMA 2001;285:562–7.
13. Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003;348:2491–9.
14. Heesakkers RA, Ho¨ vels AM, Jager GJ, et al. MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. Lancet Oncol 2008;9:850–6.
15. Weckermann D, Dorn R, Trefz M, Wagner T, Wawroschek F, Harzmann R. Sentinel lymph node dissection for prostate cancer: experience with more than 1,000 patients. J Urol 2007;177:916–20
16. Weckermann D, Dorn R, Holl G, Wagner T, Harzmann R. Limitations of radioguided surgery in high-risk prostate cancer. Eur Urol 2007;51:1549–58.
17. Mattei A, Fuechsel FG, Bhatta Dhar N, et al. The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study. Eur Urol 2008;53:118–25
18. Stone NN, Stock R, Unger P. Laparoscopic pelvic lymph node dissection for prostate cancer: comparison of the extended and modified echnique. J Urol 1997;158: 1891–4
19. Briganti A, Chun FK-H, Salonia A, et al. Complications and other surgical outcomes associated with extended pelvic lymphadenectomy inmen with localized prostate cancer. Eur Urol 2006;50:1006–13
20. Burkhard FC, Schumacher MC, Studer UE. An extended pelvic lymph-node dissection should be performed in most patients if radical prostatectomy is truly indicated.Nat Clin Pract Urol 2006;3:454–5.
21. Briganti A, Chun FK, Salonia A, et al. Critical assessment of ideal nodal yield at pelvic lymphadenectomy to accurately diagnose prostate cancer nodal metastasis in patients undergoing radical retropubic prostatectomy. Urology 2007;69:147–51.
22. Briganti A, Karakiewicz PI, Chun FK-H, et al. Percentage of positive biopsy cores can improve the ability to predict 54 lymph node invasion in patients undergoing radical prostatectomy and extended pelvic lymph node dissection. Eur Urol 2007;51:1573–81.
23. Conrad S, Graefen M, Pichlmeier U, et al. Systematic sextant biopsies improve preoperative prediction of pelvic lymph node metastases in patients with clinicallylocalized prostatic carcinoma. J Urol 1998;159:2023–9.
24. Freedland SJ, Aronson WJ, Terris MK, et al., The SEARCH Database Study Group. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database. J Urol 2003;169:2136–41.
25. Kattan MW. Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst 2003;95: 634–5.
26. Briganti A, Chun FK-H, Salonia A, et al. Validation of a nomogram predicting the probability of lymph node invasion among patients undergoing radical prostatectomy and an extended pelvic lymphadenectomy. Eur Urol 2006;49:1019–27
27. Heidenreich A, Varga Z, Von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 2002;167:1681–6.
28. Bader P, Burkhard FC, Markwalder R, Studer UE. Is a limited lymph node dissection an adequate staging procedure for prostate cancer? J Urol 2002;168:514–8.Touijer K, Rabbani F, Otero JR, et al. Standard versus limited pelvic lymph node dissection for prostate cancer in patients with a predicted probability of nodal metastasis greater than 1%. J Urol 2007;178:120–4.
29. Berglund RK, Sadetsky N, DuChane J, Carroll PR, Klein EA. Limited pelvic lymph node dissection at the time of radical prostatectomy does not affect 5-year failure rates for low, intermediate and high risk prostate cancer: results from CaPSURE. J Urol 2007;177:526–9.
30. Heidenreich A, Ohlmann CH, Polyakov S. Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy. Eur Urol 2007;52:29–37.
31. Schumacher MC, Burkhard FC, Thalmann GN, Fleischmann A, Studer UE. Is pelvic lymph node dissection necessary in patients with a serum PSA _____10 ng/ml undergoing radical prostatectomy for prostate cancer? Eur Urol 2006;50:272–9.
32. Weight CJ, Reuther AM, Gunn PW, Zippe CR, Dhar NB, Klein EA. Limited pelvic lymph node dissection does not improve biochemical relapse-free survival at 10 years after radical prostatectomy in patients with low-risk prostate cancer. Urology 2008;71:141–5.
33. Clark T, Parekh DJ, Cookson MS, et al. Randomized prospective evaluation of extended versus limited lymph node dissection in patients with clinically localized prostate cancer. J Urol 2003;169:145–7
34. Bader P, Burkhard FC, Markwalder R, Studer UE. Is a limited lymph node dissection an adequate staging procedure for prostate cancer? J Urol 2002;168:514–8.
35. Briganti A, Blute M, Eastham J, Graefen M, Heidenrich A, Karnes J, Montorsi F, Studer U. Pelvic Lymph Node Dissection in Prostate Cancer. J Urol 2009;55: 1255- 1265.
36. Masterson TA, Bianco Jr FJ, Vickers AJ, et al. The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer. J Urol 2006;175:1320–4.
37. DiMarco DS, Zincke H, Sebo TJ, Slezak J, Bergstralh EJ, Blute ML. The extent of lymphadenectomy for PTXNO prostate cancer does not effect prostate cancer outcome in the prostate specific antigen era. J Urol 2005;173: 1121–5.